AstraZeneca reports Q1 core EPS $2.58, consensus $1.27

Reports Q1 revenue $15.29B, consensus $14.92B. Pascal Soriot, CEO, AstraZeneca (AZN), said:”We delivered strong growth in Q1 2026, with Total Revenue above $15B, demonstrating our consistent commercial execution. We are advancing through our catalyst -rich period, with positive readouts for four high-value Phase III programmes since our last quarterly results, including first pivotal data for two key NMEs – tozorakimab in COPD and efzimfotase alfa in hypophosphatasia. We continue to invest in our commercial capabilities as we prepare for multiple launches, look forward to further readouts anticipated this year, and remain on track to achieve our ambition for 2030 and beyond.”